NVO(Novo Nordisk A/S) 的财务报表:医疗保健,综合制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $22.34B | $25.04B | $33.80B | $42.04B | $46.88B |
| 毛利润 | $18.59B | $21.01B | $28.60B | $35.60B | $37.96B |
| 营业利润 | $9.30B | $10.59B | $14.93B | $18.58B | $19.36B |
| 净利润 | $7.58B | $7.86B | $12.18B | $14.62B | $15.54B |
| 经营现金流 | $8.73B | $11.16B | $15.85B | $17.51B | $18.07B |
| 自由现金流 | $7.72B | $9.44B | $12.09B | $10.68B | $8.94B |
| 摊薄每股收益 | $1.65 | $1.73 | $2.71 | $3.28 | $3.49 |